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eral arterial disease (PAD). We investigated differences in quality of life (QoL) between
patients who quitted smoking during follow-up and persistent smokers.
Design: Cohort study.
Methods: Data of 711 consecutively enrolled patients undergoing vascular surgery were
collected in 11 hospitals in the Netherlands. Smoking status was obtained at baseline and at
3-year follow-up. A 5-year follow-up to measure QoL was performed with the EuroQol-5D
(EQ-5D) and Peripheral Arterial Questionnaire (PAQ).
Results: After adjusting for clinical risk factors, patients, who quit smoking within 3 years after
vascular surgery, did not report an impaired QoL (EQ-5D: odds ratio (OR) Z 0.63, 95% confi-
dence interval (CI) Z 0.28e1.43; PAQ: ORZ 0.76, 95% CIZ 0.35e1.65; visual analogue scale
(VAS): OR Z 0.88, 95% CI Z 0.42e1.84) compared with patients, who continued smoking.
Current smokers were significantly more likely to have an impaired QoL (EQ-5D: OR Z 1.86,
95% CI Z 1.09e3.17; PAQ: OR Z 1.63, 95% CI Z 1.00e2.65), although no differences in VAS
scores were found (OR Z 1.17, 95% CI Z 0.72e1.90).nt of Anesthesiology, Erasmus Medical Center, Room H805, ‘s-Gravendijkwal 230, 3015 GD Rotterdam,
; fax: þ31 10 7034957.
smusmc.nl (D. Poldermans).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
356 M.T. Hoogwegt et al.Conclusions: There was no effect of smoking cessation on QoL in PAD patients undergoing
vascular surgery. Nevertheless, given the link between smoking, complications and mortality
in this patient group, smoking cessation should be a primary target in secondary prevention.
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sclerotic disease that affects approximately 10e25% of
adults older than 55 years.1,2 Smoking is an important
modifiable risk factor for the development of PAD.3 In
patients who smoke, the diagnosis of PAD is made, on
average, a decade before the diagnosis of PAD in non-
smokers, with an observed dose-response relationship
between the amount of smoking and the development of
PAD.4 Besides a higher prevalence of PAD among people
who smoke and former smokers, those who smoke more
heavily also have an increased incidence of symptomatic,
rather than asymptomatic PAD.1 In addition, smokers with
PAD have a poorer survival rate than non-smokers with the
disease, and are twice as likely to develop complications,
such as critical limb ischaemia leading to surgery and
amputation.5 Smoking cessation is thus of utmost impor-
tance for cardiac and vascular patients. This is subscribed
by coronary artery bypass graft (CABG) surgery patients,
who can gain up to 3 life-years after smoking cessation.6,7
Recently, the impact of smoking and smoking cessation
on quality of life (QoL) has received increasing attention.
Health Related Quality of life (HRQoL) reflects the patients’
evaluation of his/her physical, psychological and social
functioning in relation to health. A number of studies have
investigated the effect of smoking on HRQoL and health
status (HS, the influence of disease on physical, emotional
and social functioning8). However, these studies were
restricted to the general population8e11 or patients with
heart disease.12e15 Mostly, smoking was found to be asso-
ciated with lower QoL.8e14 Once more, smoking was related
to a lower HS and HRQoL, both in general and after
revascularisation.12e14 The relationship between smoking
(cessation) and QoL in PAD patients is less well established,
although, as mentioned previously, smoking is an important
predictor of prognosis in this patient group,1e3 and several
studies have indicated that patients with PAD experience
impaired QoL.15,16 Therefore, we investigated the effect of
smoking and smoking cessation on QoL in a sample of PAD
patients undergoing vascular surgery during a 5-year follow-
up period. Our primary objective was to investigate
differences in QoL between patients, who quitted smoking,
and persistent smokers. A secondary objective was to
examine differences in QoL between persistent smokers
and patients, who never smoked or quit smoking before or
after baseline (non-smokers).
Methods
Study population
Between May and December 2004, data of 711 consecu-
tively enrolled patients with PAD were collected in 11
hospitals in the Netherlands. This survey was part of the
Euro Heart Survey Programme.17 The enrolled patientswere seen at the vascular surgery departments at the
participating hospitals. All patients were undergoing non-
cardiac vascular surgery (open or endovascular proce-
dures). Open procedures consisted of abdominal aortic
surgery, carotid endarterectomy or infrainguinal arterial
reconstruction. Endovascular procedures included aortic
endograft procedures and peripheral angioplasties with or
without stenting. All hospitals met the ethical requirements
considered as necessary by the medical ethics committees
of the participating hospitals.
Data collection
From the patients’ hospital charts, data on patient char-
acteristics, diagnostic procedures, cardioprotective treat-
ment and the surgical procedure were collected by trained
research assistants. All data were entered into the elec-
tronic case record form (CRF) and checked twice. Data
were transferred via the Internet to the central database at
the Erasmus Medical Center in Rotterdam, the Netherlands.
Before each upcoming follow-up moment, survival status
was obtained through the civil registries. Smoking status
was assessed at baseline, and at 3- and 5-year follow-up.
The QoL measured at 5-year follow-up was used in our
study. Additional data concerning revascularisation, reho-
spitalisation, risk factors and several aspects of daily
functioning, obtained at baseline through questionnaires,
were used.
Quality of life
HRQoL and HS were combined to form QoL. HRQoL was
measured with the Dutch version of the EuroQol Question-
naire (EQ-5D).18 The EQ-5D is a valid and reliable instru-
ment for the measurement of HRQoL in cardiac patients
that has also been shown to be responsive to changes.19 It is
a standardised, generic measure that has been used to
reflect HRQoL in patients with PAD20 and cardiac patients,
in general.19,21 The instrument consists of five items
measuring aspects of HRQoL: mobility, self-care, daily
activities, pain/discomfort and anxiety/depression. Each
item consists of three statements: ‘no problems’, ‘some
problems’ and ‘severe problems’. Patients were asked
which statement best described their health. Besides the
five questions, the EQ-5D contains a Visual Analogue Scale
(VAS), on which the respondents evaluate their health on
a scale from 0 to 100, with 100 representing good health. In
addition to the EQ-5D, the Dutch translation of the disease-
specific Peripheral Arterial Questionnaire (PAQ) was used to
measure HS. The PAQ contains 20 items, with one item
identifying the most symptomatic leg and the other items
being answered along equidistant variable Likert scales.
The Dutch version of the PAQ is composed of three sub-
domains: physical limitation, perceived disability and
Smoking Cessation and Quality of Life in PAD 357treatment satisfaction.22 The PAQ is a valid, reliable and
responsive disease-specific measure with good clinical
validity.22,23
Smoking status
Patients were characterised as quitters if they stopped
smoking between baseline and 3 years of follow-up.
Patients were considered as persistent smokers if they
smoked from 1 year before surgery and still smoked at 5
years of follow-up; patients who never smoked were clas-
sified as never smokers, while patients who quit smoking
before measurement at baseline were considered as
previous smokers. To examine the effect of smoking on
QoL, quitters, previous smokers and never smokers were
combined to form the category of non-smokers.
Data analysis
Responders were compared with non-responders by means
of the Pearson chi-square and Student’s t-tests. Baseline
demographic and clinical characteristics for the different
categories of smokers were compared using the Pearson
chi-square test and one-way analysis of variance (ANOVA),
with a post hoc Bonferroni if the ANOVA showed a signifi-
cant main effect. We determined a HRQoL score for each
patient in our data set, as well as an HS score. To compute
the five dimensions of the EQ-5D and form a utility score,Patients met 
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increase interpretability of our results in clinical practice,
the utility scores were divided into equal tertiles. To
investigate the effect of smoking and smoking cessation on
HRQoL, these scores were dichotomised into ‘low score’
versus a combination of ‘intermediate score’ and ‘high
score’. The same procedure was followed to generate ter-
tiles for the mean PAQ and VAS scores. These scores also
were dichotomised into ‘low score’ versus a combination of
‘intermediate score’ and ‘high score’. We categorised the
different vascular surgery procedures into three main
types: abdominal aortic, carotid and lower-limb surgery. By
means of univariate and multivariate logistic regression,
the effect of smoking cessation on QoL was assessed.
Because QoL after 5 years could be determined by many
factors besides smoking and smoking cessation, in multi-
variate regression analysis, we adjusted for the potential
confounding effects of demographic variables such as age
and gender, and clinical risk factors including ischaemia,
angina pectoris (AP), myocardial infarction (MI), previous
history of revascularisation, history of heart failure, cere-
brovascular disease, renal failure, diabetes mellitus (DM)
and type of surgery. Results of the logistic regression
analyses are presented as odds ratios (OR) with 95% confi-
dence intervals (CI). For all tests, a P-value <0.05 (two-
sided) was considered significant. All statistical analyses
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Responders versus non-responders
The original sample consisted of 711 patients undergoing
vascular surgery at baseline (Figure 1). After 3 years of
follow-up, 552 patients were still alive, 149 patients died
and 10 patients were lost to follow-up. A total of 200
(28.1%) patients died after 5 years of follow-up, of whom
72% were males. Their mean age was 76  9 years. At
baseline, 30% of these patients smoked. Of the remaining
patients, four emigrated, five no longer wanted to partic-
ipate in the study and 21 were lost to follow-up. All 486
surviving patients received a questionnaire, of which 390
(80.2%) responded. From these questionnaires, 364 con-
tained sufficient information to generate HRQoL scores.
With respect to the PAQ, from 384 questionnaires, an HS
score could be obtained. To investigate response bias,
responders were compared with non-responders. No
differences were found in age, gender, cardiovascular
history and clinical risk factors (all P-values > 0.05).
Baseline characteristics
General characteristics of the 390 patients at baseline are
listed in Table 1. Patients were classified as smokers
(n Z 151), quitters (n Z 55), previous smokers (n Z 166)
and never smokers (nZ 18). The mean age of patients was
64.7  9.7 years; 71.8% of the patients were males.
Previous smokers were significantly older than persistent
smokers and quitters (P < 0.001), reported a significantly
higher prevalence of ischemic heart disease (IHD), MI, and
previous revascularisation and were more likely to use
beta-blockers (P < 0.05). Never smokers more often hadTable 1 Baseline characteristics for the total study population
Total Current
smokers
N 390 (100) 151 (38.7)
Demographics
Mean age (SD) 64.7 (9.7) 62.2 (9.1)
Men 280 (71.8) 106 (70.2)
Cardiovascular history
IHD 107 (27.4) 31 (20.5)
Angina pectoris 54 (13.8) 17 (11.3)
Heart failure 9 (2.3) 2 (1.3)
MI 57 (14.6) 13 (8.6)
Stroke or TIA 50 (12.8) 11 (7.3)
Renal failure 18 (4.6) 4 (2.6)
Previous revascularisation 60 (15.4) 16 (10.6)
Hypertension 153 (39.2) 51 (33.8)
Diabetes mellitus 70 (17.9) 18 (11.9)
Medication use
Aspirin 300 (76.9) 121 (80.1)
Statins 236 (60.5) 80 (53.0)
Beta-blockers 193 (49.5) 6 (43.0)
N, number; SD, standard deviation; IHD, ischemic heart disease; MI,
a Presented as N (%), unless otherwise indicated.a prior history of cerebrovascular disease and more often
had diabetes (P < 0.05).
The effect of smoking on QoL
First, we determined the impact of smoking on QoL. The
mean scores of current smokers (n Z 151) were compared
with those of non-smokers (nZ 239) after 5 years of follow-
up. Impaired HRQoL and HS were defined as the lowest
tertile of the EQ-5D summary and VAS scores, and the
lowest tertile of the PAQ summary score, respectively. As
shown in Table 2, there were no significant differences in
the mean scores between the smoking categories
(P > 0.05). The results of the univariate and multivariate
analyses are displayed in Table 3. Analyses were adjusted
for age, gender, clinical risk factors and type of surgery.
Current smokers were significantly more likely to have an
impaired HRQoL (EQ-5D summary score: OR Z 1.84, 95%
CI Z 1.07e3.16). No differences in VAS (OR Z 1.15, 95%
CIZ 0.70e1.87) and PAQ (ORZ 1.60, 95% CIZ 0.98e2.61)
scores were found between patients, who smoked, and
patients, who did not smoke. Furthermore, older age, DM
(P < 0.01), previous ischaemia and renal failure (P < 0.05)
were significant predictors of impaired HS and HRQoL.
Impact of smoking cessation on QoL
In relation to the main aim of our study, we compared the
QoL scores between current smokers (nZ 151) and quitters
(n Z 55). Again, we adjusted for the above-mentioned
variables in multivariate regression analysis. As shown in
Table 3, quitters were less likely to report an impaired PAQ
summary score, but the predictive value of smoking cate-
gory was not significant (OR Z 0.84, 95% CI Z 0.38e1.84).and stratified by smoking status.a
Quitters Previous
smokers
Never
smokers
p-value
55 (14.1) 166 (42.6) 18 (4.6)
61.1 (7.7) 68.3 (9.2) 64.2 (14.2) <0.001
38 (69.1) 129 (77.7) 7 (38.9) 0.005
9 (16.4) 63 (38.0) 4 (22.2) 0.001
5 (9.1) 30 (18.1) 2 (11.1) 0.213
1 (1.8) 5 (3.0) 1 (5.6) 0.591
6 (10.9) 37 (22.3) 1 (5.6) 0.003
10 (18.2) 24 (14.5) 5 (27.8) 0.023
3 (5.5) 10 (6.0) 1 (5.6) 0.532
2 (3.6) 39 (23.5) 3 (16.7) 0.001
22 (40.0) 73 (44.0) 7 (38.9) 0.325
13 (23.6) 33 (19.9) 6 (33.3) 0.041
39 (70.9) 128 (77.1) 12 (66.7) 0.381
36 (65.5) 111 (66.9) 9 (50.0) 0.051
23 (41.8) 96 (57.8) 9 (50.0) 0.038
myocardial infarction; TIA, transient ischemic attack.
Table 2 Mean scores on HRQoL and HS measures stratified by smoking status.
Mean Total Current smokers Quitters Previous smokers Never smokers p-value
EQ-5D
N 364 143 51 155 15
Score (SD) 0.77  0.23 0.77  0.23 0.78  0.22 0.76  0.23 0.83  0.17 0.708
% impaired 26.60 28.70 23.50 27.10 13.30 0.587
VAS
N 377 146 55 158 18
Score (SD) 68.65  18.67 69.25  18.22 68.11  18.57 68.14  19.85 69.89  11.59 0.942
% impaired 32.60 31.50 30.90 34.80 27.80 0.875
PAQ
N 384 148 54 164 18
Score (SD) 61.24  26.73 62.69  27.52 62.29  27.01 59.69  26.27 60.31  24.71 0.780
% impaired 33.30 35.10 31.50 31.70 38.90 0.863
EQ-5D, EuroQol; SD, standard deviation; VAS, visual analogue scale; PAQ, peripheral arterial questionnaire.
Smoking Cessation and Quality of Life in PAD 359Quitting smoking neither had a significant impact on the
EQ-5D summary score (ORZ 0.64, 95% CIZ 0.28e1.47) nor
on the VAS score (ORZ 0.92, 95% CIZ 0.44e1.94). On the
other hand, older age, having DM, ischaemia and renal
failure were significant predictors of an impaired HRQoL
and HS (all P < 0.05), and having had a previous revascu-
larisation procedure was predictive for an impaired HS
(P < 0.05).Discussion
Our main finding is that there is no significant effect of
smoking cessation on QoL in patients with PAD. Patients,
who quit smoking within 3 years after vascular surgery,
neither experienced a change in QoL compared to patients
who kept smoking. To our knowledge, only a few studies
have investigated the effect of smoking cessation in the
high-risk population of PAD patients. Since smoking cessa-
tion is an enormous challenge for addicted patients, it is
important to recognise that smoking cessation does not
influence the QoL of patients with PAD negatively. Besides,
the need for smoking cessation, which still receives very
little attention, has to be emphasised both to the patients
and to the physicians.24 In CABG patients, smoking cessa-
tion had a greater effect on enhancing survival than any
other form of intervention.6,25 Hence, patients should be
encouraged to quit smoking, which could be facilitated by
attending rehabilitation programmes. Through motiva-
tional counselling and behavioural therapy by a psycholo-
gist, the chances for successful quitting can be increased.26
Besides these interventions, additional assistance including
nicotine replacement therapy and pharmacological
therapy, including varenicline27 and bupropion,28 can be
applied.
Our results on the effect of smoking cessation on QoL
do not fully match with some earlier findings. Several
studies among university graduates, nurses and adults in
the US found that smoking cessation resulted in a better
HRQoL9,11 and less depressive symptoms and life dissat-
isfaction.29 However, these studies were all conducted in
segments of the general population. Although smokers areexpected to experience health benefits from cessation as
compared with continued smokers, some of these health
improvements may not directly be translated into
perceptions of improvement of QoL. This could, in
particular, be the case when chronic illnesses such as PAD
are present. Other factors could be more important in
determining QoL. Since PAD patients are mostly people
smoking for a few decades, this could clarify the lack of
significance in our study. In coronary artery disease (CAD),
patients who stopped smoking at the time of revascular-
isation experienced more improvements in HRQoL than
patients who continued to smoke.13 Nevertheless, the
poor prognosis of PAD patients compared with CAD
patients, partly explained by disease characteristics,
receiving less cardiac medication than CAD patients, and
more perioperative and long-term complications could
possibly diminish the positive effect of smoking cessation
on QoL in this vulnerable patient group.25 Another
explanation could be that smokers may quit after
becoming symptomatic or getting a co-morbid condition
related to tobacco use. The possibly positive effect of
smoking cessation may diminish by the negative effect of
the co-morbid disease. Finally, maybe the negative
effects of smoking have already had their effect, and it
could be too late for the quitters to improve their QoL.
Our secondary objective was to determine possible
differences in QoL between current smokers and non-
smoking patients. Current smokers were more likely to have
an impaired QoL than patients, who did not smoke, indi-
cating that smoking had a negative impact on QoL in our
group of PAD patients. These results are in line with the
earlier findings, showing a poorer HRQoL and more mental
and physical distress among current smokers.14,29 In addi-
tion, smokers were more likely to have activity limitations
due to greater impairments. Among heart failure patients,
those who smoked were found to have a significant lower
HS score than former smokers or patients who never
smoked.12 Taira and colleagues found that revascularisation
in patients with symptomatic CAD leads to improved
HRQoL, although patients who smoked improved substan-
tially less (up to 75%) than patients who did not smoke.13 In
our study, no effect of smoking on the domains of the PAQ
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360 M.T. Hoogwegt et al.and EQ-5D was found in the unadjusted analysis. This may
be explained by the relatively large group of previous
smokers, which is older and more often has a history of
cardiovascular disease than current smokers, quitters and
never smokers. When comparing scores on the domains of
the QoL questionnaires, the impaired QoL of previous
smokers due to older age and a burden of previous
cardiovascular history30e32 may suppress the negative
effect of smoking on QoL. By adjusting these variables in
multivariate analysis, we did find a significant negative
effect of smoking on QoL.
Another important finding of our study is that never
smokers more often had a prior history of cerebrovascular
disease and had diabetes. At first sight, this may seem
puzzling, but when considering the group of never smokers
in detail, the explanation might be quite logical. In our
group of patients, only 4.2% had a history of never having
smoked. The other 95.8% still smoked or had been smoking
for a great part of their life. Based on these percentages,
and since smoking has proved to be a major risk factor for
the development of PAD, the non-smokers are likely to
develop PAD due to reasons other than smoking. This
conclusion is further supported by other results of our
study, which display a higher frequency of IHD, MI and
previous revascularisation among previous smokers, than
among current smokers. Maybe for this subgroup of
patients, these events have motivated them to quit
smoking.
This study has some limitations. First, all patients
underwent a vascular intervention, which may limit gen-
eralisability to the general PAD population. Moreover,
confounding might have played a role, as smoking is
associated with a variety of other conditions such as
pulmonary disease, cancer and psychiatric conditions,
which we were unable to adjust for statistically.32,33 A
third limitation is the low number of patients, who quit
smoking after revascularisation. With a larger group of
quitters, we potentially would have been able to deter-
mine a clearer effect of smoking cessation on QoL.
Another limitation is that smoking status was based on
self-report, rather than an objective measure, such as
exhaled carbon monoxide, which could lead to under-
estimation of the actual amount of smoking patients.34
Fifth, there might be a selection bias due to non-
response and death, with the likelihood that these
patients would have had a worse QoL, given that HS has
proven to be an independent predictor of prognosis in
patients with PAD,35 or with the likelihood that only the
current smokers with best health and better QoL survived.
A final limitation is related to the study design, as we had
no information on the baseline QoL.
In conclusion, in the current study, we found no effect of
smoking cessation on QoL in PAD patients undergoing
vascular surgery. Nevertheless, smoking cessation should
still be a primary target in secondary prevention, given that
smoking enhances the risk of severe complications and
mortality in this patient group. Future studies are war-
ranted to replicate the findings of the current studies;
however, in the meantime, more attention should be paid
to lifestyle changes and risk factor management in this
patient group, both by the physicians and by the patients
themselves.
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